Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease

Open access

Abstract

A previously published clinical trial demonstrated the benefit of autologous CD34(+) cells transduced with a selfinactivating lentiviral vector (HPV569) containing an engineered β-globin gene (β(A-T87Q)-globin) in a subject with β thalassemia major. This vector has been modified to increase transduction efficacy without compromising safety. In vitro analyses indicated that the changes resulted in both increased vector titers (3 to 4 fold) and increased transduction efficacy (2 to 3 fold). An in vivo study in which 58 β-thalassemic mice were transplanted with vector- or mock-transduced syngenic bone marrow cells indicated sustained therapeutic efficacy. Secondary transplantations involving 108 recipients were performed to evaluate long-term safety. The six month study showed no hematological or biochemical toxicity. Integration site (IS) profile revealed an oligo/polyclonal hematopoietic reconstitution in the primary transplants and reduced clonality in secondary transplants. Tumor cells were detected in the secondary transplant mice in all treatment groups (including the control group), without statistical differences in the tumor incidence. Immunohistochemistry and quantitative PCR demonstrated that tumor cells were not derived from transduced donor cells. This comprehensive efficacy and safety data provided the basis for initiating two clinical trials with this second generation vector (BB305) in Europe and in the USA in patients with β-thalassemia major and sickle cell disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1566523214666141127095336

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. (1) In vitro evaluation of LentiGlobin lentiviral vectors. A) Diagram of the LentiGlobin HPV569 and BB305 lentiviral vectors. The 3′ β-globin enhancer, the 372 base pairs (bp) IVS2 deletion in intron 2 (triangle), the βA-T87Q mutation (ACA [Thr] to CAG [Gln]) and DNase I hypersensitive sites (HS) 2, HS3, and HS4 of the human β-globin locus control region (LCR) are indicated. Safety modifications including the 400 bp deletion in the U3 of the right HIV LTR, the rabbit β-globin polyA signal and the 2 × 250 bp cHS4 chromatin insulators are indicated. βp, human β-globin promoter; cPPT/flap, central polypurine tract; HIV LTR, human immunodeficiency type-1 virus long-terminal repeat; ppt, polypurine tract; RRE, Rev-responsive element; Ψ+, packaging signal. B) Functional (transducing unit/mL) and physical (ng p24/mL) titers of lentiviral vectors produced in HEK293T cells, before (harvest) and after purification/concentration (final). C) Y axis: Vector copies = Average vector copy number per cell in transduced human CD34+ cells. D) Y axis: Vector copies = Average vector copy numbers per cell in transduced progenitor cells, using either short-term cultures to determine colony forming cells (CFCs) or long-term cultures to determine long-term culture initiating cells (LTC-ICs). MOI was 50. E) HPLC profile of globin chains from pooled erythroid colonies obtained from HPV569 (top) and BB305 (bottom) lentiviral vector-transduced CD34+ cells. F) Y axis: βA-T87Q globin chains as a percentage of all non-α globin chains as detected by HPLC.
Fig. (1) In vitro evaluation of LentiGlobin lentiviral vectors. A) Diagram of the LentiGlobin HPV569 and BB305 lentiviral vectors. The 3′ β-globin enhancer, the 372 base pairs (bp) IVS2 deletion in intron 2 (triangle), the βA-T87Q mutation (ACA [Thr] to CAG [Gln]) and DNase I hypersensitive sites (HS) 2, HS3, and HS4 of the human β-globin locus control region (LCR) are indicated. Safety modifications including the 400 bp deletion in the U3 of the right HIV LTR, the rabbit β-globin polyA signal and the 2 × 250 bp cHS4 chromatin insulators are indicated. βp, human β-globin promoter; cPPT/flap, central polypurine tract; HIV LTR, human immunodeficiency type-1 virus long-terminal repeat; ppt, polypurine tract; RRE, Rev-responsive element; Ψ+, packaging signal. B) Functional (transducing unit/mL) and physical (ng p24/mL) titers of lentiviral vectors produced in HEK293T cells, before (harvest) and after purification/concentration (final). C) Y axis: Vector copies = Average vector copy number per cell in transduced human CD34+ cells. D) Y axis: Vector copies = Average vector copy numbers per cell in transduced progenitor cells, using either short-term cultures to determine colony forming cells (CFCs) or long-term cultures to determine long-term culture initiating cells (LTC-ICs). MOI was 50. E) HPLC profile of globin chains from pooled erythroid colonies obtained from HPV569 (top) and BB305 (bottom) lentiviral vector-transduced CD34+ cells. F) Y axis: βA-T87Q globin chains as a percentage of all non-α globin chains as detected by HPLC.CC BY-NC · PubMed Central
Fig. (2) Design of in vivo transplant studies and primary transplant results. A) Study design. Lin- bone marrow cells from β-thalassemia mice (Hbbth1/th1 ; β-thal CD45.2) mice were transduced with lentiviral vectors and infused in 58 syngenic recipients. Four months after primary transplantation, the remaining 54 animals were sacrificed and bone marrow cells were injected in 108 secondary normal mice. The numbers of prematurely dead mice are indicated on top of the arrows. B) Mean (± SD) percentage chimerism estimated in primary transplant recipients. C) Mean VCN (± SD) pre-transplantation (in vitro), and in blood at 2 and 3 months after transplantation (2M, 3M), and in bone marrow after sacrifice (whole bone marrow and after culture for CFCs). D) Proportion of therapeutic β-globin chains and correction of the β-thalassemic phenotype (hemoglobin concentration and reticulocyte percentage) per group of mice. Horizontal bar represents the mean.
Fig. (2) Design of in vivo transplant studies and primary transplant results. A) Study design. Lin- bone marrow cells from β-thalassemia mice (Hbbth1/th1 ; β-thal CD45.2) mice were transduced with lentiviral vectors and infused in 58 syngenic recipients. Four months after primary transplantation, the remaining 54 animals were sacrificed and bone marrow cells were injected in 108 secondary normal mice. The numbers of prematurely dead mice are indicated on top of the arrows. B) Mean (± SD) percentage chimerism estimated in primary transplant recipients. C) Mean VCN (± SD) pre-transplantation (in vitro), and in blood at 2 and 3 months after transplantation (2M, 3M), and in bone marrow after sacrifice (whole bone marrow and after culture for CFCs). D) Proportion of therapeutic β-globin chains and correction of the β-thalassemic phenotype (hemoglobin concentration and reticulocyte percentage) per group of mice. Horizontal bar represents the mean.CC BY-NC · PubMed Central
Fig. (3) Integration site analysis in primary transplants. A) Total sequencing reads, numbers of unique IS with duplicates in pre- and post-transplant samples and unique IS without duplicates combining male and female data. B) Top ten IS pre- and post-transplantation in all groups of mice receiving transduced cells. C) Percentage of IS within genes and in genes +/- 10kb. D) Percentage of IS upstream and downstream of the transcription start site (TSS).
Fig. (3) Integration site analysis in primary transplants. A) Total sequencing reads, numbers of unique IS with duplicates in pre- and post-transplant samples and unique IS without duplicates combining male and female data. B) Top ten IS pre- and post-transplantation in all groups of mice receiving transduced cells. C) Percentage of IS within genes and in genes +/- 10kb. D) Percentage of IS upstream and downstream of the transcription start site (TSS).CC BY-NC · PubMed Central
Fig. (4) Integration site analysis in secondary transplants. A) Percentage of IS within genes and in genes +/- 10kb. B) Percentage of IS upstream and downstream of the transcription start site (TSS). C) Top ten IS comparing primary and secondary transplanted animals. D) Diversity index in pre- and post-transplant samples.
Fig. (4) Integration site analysis in secondary transplants. A) Percentage of IS within genes and in genes +/- 10kb. B) Percentage of IS upstream and downstream of the transcription start site (TSS). C) Top ten IS comparing primary and secondary transplanted animals. D) Diversity index in pre- and post-transplant samples.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Research works printed but not linked: 2

  1. [32]Morawietz G. Ruehl-Fehlert C. Kittel B. Revised guides for organ sampling and trimming in rats and mice--Part 3. A joint publication of the RITA and NACAD groups. Exp. Toxicol. Pathol. 2004 55 433 449 15384249
  2. [40]Negre O. Bartholoma C. Kutner R. Abstract 674 of the American Society of Gene & Cell Therapy (ASGGT) 16th Annual Meeting. May 15-18, 2013. Salt Lake City, Utah, USA. Mol. Ther. 2013 21 Suppl. 1 s257 23728215

Cited by

See all 126

Metadata

Authors
Negre, O., Bartholomae, C., Beuzard, Y., Cavazzana, M., Christiansen, L., Courne, C., Deichmann, A., Denaro, M., Dreuzy, E., Finer, M., Fronza, R., Gillet-Legrand, B., Joubert, C., Kutner, R., Leboulch, P., Maouche, L., Paulard, A., Pierciey, F., Rothe, M., Ryu, B., Schmidt, M., Kalle, C., Payen, E., & Veres, G.
Affiliations
  • German Cancer Research Center (DE)
  • Université Paris-Saclay (FR)
  • Bluebird Bio (France) (FR)
  • Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
  • Harvard University (US)
  • Medizinische Hochschule Hannover (DE)
Corresponding author
  • Payen, Emmanuel
  • Veres, Gabor
Venue
Current Gene Therapy
Published
2014-12-26
Volume
15
Issue
1
Pages
64-81
ISSN
1566-5232 (ISSN-L)
OpenAlex
W2116613468
Cited by
126
References
59
Citations by year
2026: 6 · 2025: 10 · 2024: 8 · 2023: 9 · 2022: 9 · 2021: 17 · 2020: 9 · 2019: 12 · 2018: 14 · 2017: 12 · 2016: 15 · 2015: 5
FWCI
7.01
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Current Gene Therapy (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Funders
  • bluebird bio
  • Agence Nationale de la Recherche
  • Institut National de la Santé et de la Recherche Médicale
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords
beta-thalassemia major, sickle cell disease, lentiviral vectors, self-inactivating vectors, beta-globin gene, vector titer, bone marrow transplantation, serial transplantation, hematopoietic recovery, tumor incidence, gene therapy safety
MeSH terms
Anemia, Sickle Cell, Animals, Disease Models, Animal, DNA Damage, Female, Genetic Vectors, Male, Mice, Inbred C57BL, Genetic Therapy, Gene Expression, Lentivirus, beta-Thalassemia, Gene Transfer Techniques, Hematopoietic Stem Cell Transplantation, Antigens, CD34, Computational Biology, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease. https://app.cochat.ai/papers/10.2174/1566523214666141127095336
The paper
Negre, O., Bartholomae, C., Beuzard, Y., Cavazzana, M., Christiansen, L., Courne, C., Deichmann, A., Denaro, M., Dreuzy, E., Finer, M., Fronza, R., Gillet-Legrand, B., Joubert, C., Kutner, R., Leboulch, P., Maouche, L., Paulard, A., Pierciey, F., Rothe, M., . . . Veres, G. (2014). Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease. Current Gene Therapy. https://doi.org/10.2174/1566523214666141127095336

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.